Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm WK, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy 2024 Apr 2. doi: 10.1111/all.16108.
PMID: 38563683